摘要
目的:探讨孟鲁司特钠联合氯雷他定治疗过敏性紫癜患儿的疗效及对血清TNF-α、IL-6及骨桥蛋白(OPN)水平的影响。方法 :选取初发过敏性紫癜患儿64例随机分为对照组和观察组各32例。对照组给予孟鲁司特钠治疗,而观察组则在对照组的基础上联合氯雷他定治疗。比较两组患者临床疗效、不良反应以及治疗后紫癜、血尿、腹痛和关节疼痛的消失时间,检测并观察两组患者治疗前后血清TNF-α、IL-6及OPN水平的变化。结果 :观察组治疗的总有效率为87.50%,显著高于对照组的62.50%(P<0.05)。观察组患者的紫癜、血尿、腹痛和关节疼痛的消失时间,以及治疗后血清TNF-α、IL-6和OPN水显著低于对照组(P<0.05);两组患者治疗过程中均未出现严重的不良反应。结论 :孟鲁司特钠联合氯雷他定治疗过敏性紫癜,可有效改善患儿的临床症状,且还能调节血清TNF-α、IL-6及OPN水平,疗效确切,安全性好,研究结果可作为临床参考。
Objective： To discuss the effect of montelukast sodium combined with loratadine in the treatment of children with allergic purpura and on the levels of TNF-α, IL-6 and OPN. Methods： Sixty-four children with allergic purpura were randomly selected and divided into a control group （treated with montelukast sodium） and an observation group （treated with loratadine besides montelukast sodium） with 32 cases each. The clinical effects, adverse reactions and the time for the disappearance of purpura, hematuresis, stomachache and arthralgia were compared between the two groups after treatment. The levels of TNF-α, IL-6 and OPN before and after treatments were observed. Results： The total effective rate was significantly higher in the observation group than in the control group （87.50% vs 62.50%, P〈0.05）. The time for the disappearance of purpura, hematuresis, stomachache and arthralgia and the levels of TNF-α, IL-6 and OPN were shorter or lower in the observation group than in the control group （P〈0.05）. There were no severe adverse reactions occurred in two groups. Conclusion： The combination therapy for the treatments of allergic purpura can improve clinical symptoms and regulate the levels of TNF-α, IL-6 and OPN with clear efficacy and good safety and is worthy of clinical use.
作者
陈小凡
CHEN Xiaofan(Department of Pediatrics, the First People＇s Hospital of Xiushui County in Jiujiang City, Jiujiang 332000, Chin)
出处
《上海医药》
CAS
2017年第3期31-34,共4页
Shanghai Medical & Pharmaceutical Journal
基金
2015年江西省卫生厅科研计划课题(普通)(项目编号:20154004)
